Trial Profile
A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Eribulin (Primary) ; Cyclophosphamide; Docetaxel
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- 03 Oct 2016 Status changed from active, no longer recruiting to completed.
- 15 Jul 2016 Planned End Date changed from 1 Mar 2016 to 1 Sep 2016.
- 12 Dec 2015 Results presented at the 38th Annual San Antonio Breast Cancer Symposium